The Amgen logo will be exhibited on May 17, 2023 outside the Ambem headquarters in Thousand Oaks, California.
Mario Tama | Getty pictures
Amgen On Wednesday, there were two critical studies in the late stage for his experimental weight loss injection Maritide, another step in his offer to get into the booming market for obesity.
“We are pleased to tell that these attempts have now been initiated, and the progress of the maritime program was really, very well,” said Dr. Jay Bradner, Executive Vice President for Research and Development of Amgen, during a TD COWEN conference using the name of the phase -three -development program of the drug.
Maritide is a monthly injection from which investors hope Novo Nordisk And Eli LillyThe weekly injections are. They are part of a class of drugs called GLP-1 and imitate certain hormones that are manufactured in the intestine to tamp the appetite and regulate the blood sugar.
According to a survey by the KFF health guideline, around 6% used by US-growing or more than 15 million people a recipe for GLP-1S. Some analysts expect the GLP-1 market to be worth more than $ 150 billion annually in the early 2030s.
One of the new studies in phase three is the examination of Amgen's medication in around 3,500 people with obesity or overweight who are overweight without type -2 diabetes, said Bradner. The second study examines Maritide in 999 patients who are overweight or overweight and have type -2 diabetes
The main goal of both studies is to measure the percentage of weight loss after 72 weeks. Amgen will examine three target cans from Maritide and plans to use a dose for an escalation or to start patients with a lower dose of the drug and to increase this amount over time. The company did not share a specific regime for dosing in the experiments.
Amgen said in November in November that Maritide helped patients with obesity to lose up to 20% of their weight after one year in a phase -Two study without weight loss plateau. The drug also helped patients with obesity and type -2 diabetes up to 17% of their weight after one year without a plateau. However, the results were at the lower end of the high expectations of Wall Street.
Amgen will report more data on Maritide this year. The complete results of the phase -Two study will be presented in June at the American Diabetes Association Conference. The company continues to investigate patients in an expansion of this study, which will read aloud in the second half of this year.
Maritide brings a new approach to weight loss compared to the existing medicines on the market, since it is a so-called peptide antibody conjugate, which refers to a monoclonal antibody connected with two peptides. The peptides activate receptors of an intestinal hormone called GLP-1, while the antibody blocks the receptors of another hormone, the gip called Gip.
This is different from Eli Lilly's obese drug medication, Zepbound, which activates both GIP and GLP-1. Novo Nordisks Wegvy activates GLP-1, but does not aim at Gip, which can also influence how the body breaks sugar and fat.
